Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy
Author
Liu, YaminAfzal, Junaid
Vakrou, Styliani
Greenland, Gabriela V
Talbot, C Conover
Hebl, Virginia B
Guan, Yufan
Karmali, Rehan
Tardiff, Jil C
Leinwand, Leslie A
Olgin, Jeffrey E
Das, Samarjit
Fukunaga, Ryuya
Abraham, M Roselle
Affiliation
Univ Arizona Hlth Sci, Sarver Heart CtrIssue Date
2019-12-17
Metadata
Show full item recordPublisher
FRONTIERS MEDIA SACitation
Liu Y, Afzal J, Vakrou S, Greenland GV, Talbot CC Jr, Hebl VB, Guan Y, Karmali R, Tardiff JC, Leinwand LA, Olgin JE, Das S, Fukunaga R and Abraham MR (2019) Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy. Front. Cardiovasc. Med. 6:170. doi: 10.3389/fcvm.2019.00170Rights
Copyright © 2019 Liu, Afzal, Vakrou, Greenland, Talbot, Hebl, Guan, Karmali, Tardiff, Leinwand, Olgin, Das, Fukunaga and Abraham. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background: Hypertrophic cardiomyopathy (HCM) is characterized by myocyte hypertrophy and fibrosis. Studies in two mouse models (R92W-TnT/R403Q-MyHC) at early HCM stage revealed upregulation of endothelin (ET1) signaling in both mutants, but TGFβ signaling only in TnT mutants. Dysregulation of miR-29 expression has been implicated in cardiac fibrosis. But it is unknown whether expression of miR-29a/b/c and profibrotic genes is commonly regulated in mouse and human HCM. Methods: In order to understand mechanisms underlying fibrosis in HCM, and examine similarities/differences in expression of miR-29a/b/c and several profibrotic genes in mouse and human HCM, we performed parallel studies in rat cardiac myocyte/fibroblast cultures, examined gene expression in two mouse models of (non-obstructive) HCM (R92W-TnT, R403Q-MyHC)/controls at early (5 weeks) and established (24 weeks) disease stage, and analyzed publicly available mRNA/miRNA expression data from obstructive-HCM patients undergoing septal myectomy/controls (unused donor hearts). Results: Myocyte cultures: ET1 increased superoxide/H2O2, stimulated TGFβ expression/secretion, and suppressed miR-29a expression in myocytes. The effect of ET1 on miR-29 and TGFβ expression/secretion was antagonized by N-acetyl-cysteine, a reactive oxygen species scavenger. Fibroblast cultures: ET1 had no effect on pro-fibrotic gene expression in fibroblasts. TGFβ1/TGFβ2 suppressed miR-29a and increased collagen expression, which was abolished by miR-29a overexpression. Mouse and human HCM: Expression of miR-29a/b/c was lower, and TGFB1/collagen gene expression was higher in TnT mutant-LV at 5 and 24 weeks; no difference was observed in expression of these genes in MyHC mutant-LV and in human myectomy tissue. TGFB2 expression was higher in LV of both mutant mice and human myectomy tissue. ACE2, a negative regulator of the renin-angiotensin-aldosterone system, was the most upregulated transcript in human myectomy tissue. Pathway analysis predicted upregulation of the anti-hypertrophic/anti-fibrotic liver X receptor/retinoid X receptor (LXR/RXR) pathway only in human myectomy tissue. Conclusions: Our in vitro studies suggest that activation of ET1 signaling in cardiac myocytes increases reactive oxygen species and stimulates TGFβ secretion, which downregulates miR-29a and increases collagen in fibroblasts, thus contributing to fibrosis. Our gene expression studies in mouse and human HCM reveal allele-specific differences in miR-29 family/profibrotic gene expression in mouse HCM, and activation of anti-hypertrophic/anti-fibrotic genes and pathways in human HCM.Note
Open access journalISSN
2297-055XPubMed ID
31921893Version
Final published versionSponsors
Innovator Project Award (American Heart Association)American Heart Association; UCSF Division of Cardiology; Assistant Secretary of Defense for Health Affairs through the FY17 PRMRP Discovery [W81XWH17-PRMRP-DA]ae974a485f413a2113503eed53cd6c53
10.3389/fcvm.2019.00170
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2019 Liu, Afzal, Vakrou, Greenland, Talbot, Hebl, Guan, Karmali, Tardiff, Leinwand, Olgin, Das, Fukunaga and Abraham. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Related articles
- Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy.
- Authors: Vakrou S, Liu Y, Zhu L, Greenland GV, Simsek B, Hebl VB, Guan Y, Woldemichael K, Talbot CC, Aon MA, Fukunaga R, Abraham MR
- Issue date: 2021 Jun 23
- Allele-specific dysregulation of lipid and energy metabolism in early-stage hypertrophic cardiomyopathy.
- Authors: Vaniya A, Karlstaedt A, Gulkok D, Thottakara T, Liu Y, Fan S, Eades H, Vakrou S, Fukunaga R, Vernon HJ, Fiehn O, Roselle Abraham M
- Issue date: 2024 Jun
- Single-nucleus RNA/ATAC-seq in early-stage HCM models predicts SWI/SNF-activation in mutant-myocytes, and allele-specific differences in fibroblasts.
- Authors: Thottakara T, Padmanabhan A, Tanriverdi T, Thambidurai T, Diaz-Rg JA, Amonkar SR, Olgin JE, Long CS, Roselle Abraham M
- Issue date: 2024 Apr 24
- Lumican accumulates with fibrillar collagen in fibrosis in hypertrophic cardiomyopathy.
- Authors: Rixon C, Andreassen K, Shen X, Erusappan PM, Almaas VM, Palmero S, Dahl CP, Ueland T, Sjaastad I, Louch WE, Stokke MK, Tønnessen T, Christensen G, Lunde IG
- Issue date: 2023 Apr
- MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.
- Authors: Maurer B, Stanczyk J, Jüngel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S, Distler O
- Issue date: 2010 Jun